However, for mutant IDH tumour cells, due to a lack of antioxidants and a high level of the TCA cycle, these tumour cells could produce more ROS [284,285], which leads to an increase in the sensitivity of radiotherapy and chemotherapy to mutant IDH patients, but not to the susceptibility of wild-type IDH tumour cells [270,286]. The gene discussed is IDH1; the disease is neoplasm.